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Abstract
Previous work has demonstrated that variants of a heme protein, Rhodothermus marinus 
cytochrome c (Rma cyt c), catalyze abiological carbene boron–hydrogen (B–H) bond insertion 
with high efficiency and selectivity. Here we investigated this carbon–boron bondforming 
chemistry with cyclic, lactone-based carbenes. Using directed evolution, we obtained a Rma cyt c 
variant BORLAC that shows high selectivity and efficiency for B–H insertion of 5- and 6-
membered lactone carbenes (up to 24,500 total turnovers and 97.1:2.9 enantiomeric ratio). The 
enzyme shows low activity with a 7-membered lactone carbene. Computational studies revealed a 
highly twisted geometry of the 7membered lactone carbene intermediate relative to 5- and 6-
membered ones. Directed evolution of cytochrome c together with computational characterization 
of key iron-carbene intermediates has allowed us to expand the scope of enzymatic carbene B–H 
insertion to produce new lactone-based organoborons.
Graphical Abstract
Keywords
cytochrome c; carbene; organoboron; lactones; biocatalyst; directed evolution
Supporting Information
Supporting information for this article is available online at https://doi.org/10.1055/s-0037-1611662.
HHS Public Access
Author manuscript
Synlett. Author manuscript; available in PMC 2019 March 27.
Published in final edited form as:





















The significant role of organoboron chemistries1–3 in synthetic methodologies is exemplified 
by alkene hydroboration4,5 and Suzuki cross-coupling,6,7 whose enormous footprints in 
synthetic chemistry have been recognized by Nobel Prizes. In addition, organo-boronic acids 
or -borates8 can act as transition-state-analog inhibitors in biological systems and are useful 
functionalities in chemotherapeutics9 and other biologically active molecules.10 The broad 
applications of organoboron compounds have prompted chemists to develop efficient, 
selective and modular synthetic platforms for installing boron motifs onto carbon backbones. 
One major class of methods for forming carbon– boron (C–B) bonds relies on transition-
metal-catalyzed B–H bond insertion of carbenes (Figure 1A),11–18 as introduced by Curran 
and co-workers. Recently, the Arnold laboratory developed the first biocatalytic system for 
this transformation using engineered variants of cytochrome c from the Gram-negative, 
thermohalophilic bacterium Rhodothermus marinus (Rma cyt c).19 The laboratory-evolved 
enzymes exhibited very high efficiency (up to 15,300 turnovers and 6,100 h−1 turnover 
frequency) and enantioselectivity (up to 99:1 enantiomeric ratio) with different carbenes and 
boranes (Figure 1B).
To expand the catalytic range of this enzymatic C–B bond-forming platform, we have 
engineered Rma cyt c to accept structurally different carbenes. In previous work, we 
typically used α-ester-substituted diazo compounds as carbene precursors,19 but we recently 
demonstrated that Rma cyt c mutants can be tuned to use a spectrum of α-trifluoromethyl-α-
alkyl diazo compounds to furnish a wide array of chiral α-trifluoromethylated organoborons 
(Figure 1C).20 We were curious whether cyclic carbene moieties21 can also be used by Rma 
cyt c, despite significant structural differences compared to the acyclic carbenes used in 
previous work.19–26
We started this investigation of cyclic carbenes using five-membered lactone diazo 
compound 1 (see Figure 3) as the carbene precursor. With such a rigid structure, the putative 
iron-porphyrin carbene (IPC) intermediate is expected to have different conformational 
properties and potentially distinct electronic features compared to acyclic carbenes, such as 
the one derived from α-methyl ethyl diazoacetate (Me-EDA). Recent work by our group 
revealed the crystal structure of the Me-EDA-derived IPC intermediate27 in a triple mutant 
of Rma cyt c (V75T M100D M103E (TDE)) evolved in the laboratory for Si–H bond 
insertion.26 Experiments indicated a singlet electronic state of this iron carbene species 
IPC1, which is in line with the computational result that open/closed-shell singlets are the 
dominant electronic states (Figure 2).
We used density functional theory (DFT) calculations to assess the electronic states of the 
lactone-based IPC2 (also using the simplified model of the protein IPC).21,27–30 As we 
expected, IPC2 features a near-planar geometry with a very small dihedral angle d(Fe-C-C-
O) (<13°) in all electronic states, which is very different from the acyclic IPC1 with d(Fe-C-
C-O) of nearly 90° in singlets. The small dihedral angle renders the singlet states less stable 
due to strong repulsion between fully occupied orbitals and thus significantly changes the 
energy levels of the electronic states of the IPC.
We wanted to know how the different structural and electronic properties of this intermediate 
affect carbene B–H insertion. We thus tested the borylation reaction using the five-
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membered lactone diazo compound 1 and an N-heterocyclic carbene (NHC)-stabilized 
borane as substrates in the presence of whole E. coli bacteria expressing engineered variants 
of Rma cyt c, starting with those obtained during directed evolution for borylation with 
acyclic carbene precursors (e.g., Me-EDA) (Figure 3). We were pleasantly surprised to see 
that wild-type Rma cyt c exhibited high efficiency for lactone carbene B–H insertion, with 
960 total turnovers (TTN) and 70% gas chromatography (GC) yield. The enantioselectivity, 
however, was poor, with only a 68:32 enantiomeric ratio (e.r.). A distal axial-ligand M100D 
mutation, previously discovered to facilitate both carbene Si–H and B–H insertion,19,26 
improved the yield, but did not improve the enantiocontrol of this reaction. Residue V75 in 
an α-helix region was previously shown to affect carbene orientation.19,20 Screening of 
M100D variants containing mutations at V75 identified M100D V75R as the most selective, 
with 93.3:6.7 e.r., whereas V75T/C/K/P/G mutations resulted in poor to moderate 
enantioselectivities. An additional M103V mutation led to even more precise stereochemical 
control, giving an e.r. of 94.9:5.1 (Figure 3).
To increase the enantioselectivity of lactone-carbene B– H insertion, we subjected the Rma 
cyt c V75R M100D M103V (RDV) variant to site-saturation mutagenesis, targeting active-
site amino acid residues which are close to the iron center in wild-type Rma cyt c (within 10 
Å). It is known that the residues residing on the flexible front loop are important for 
controlling the structure of the heme pocket, which is presumably the active site for this 
novel function (Figure 3A).27 Consequently, introducing suitable mutations on this loop may 
help to orient the iron-carbene intermediate or tune the approach of the borane substrate and 
lead to desired enantioselectivity. A double-site-saturation mutagenesis library at residues 
M99 and T101 was cloned using the 22-codon-trick protocol32 and screened as whole-cell 
catalysts in four 96-well plates for improved borylation enantioselectivity. Double mutant 
M99Q T101Y (BORLAC) was identified to exhibit higher selectivity (96.3:3.7 e.r.) and good 
catalytic efficiency (970 TTN, 80% GC yield).
With an efficient and selective borylating variant BORLAC in hand, we then assessed the 
scope of boranes that this platform can use (Figure 4A). Boranes without stabilizing groups 
are highly reactive and unstable in aqueous conditions. Lewis bases, such as ethers, amines, 
phosphines and NHCs, are generally used as good stabilizing groups for free boranes.33 
Considering the biocompatibility and cell permeability of the borane reagents, NHC-
stabilized boranes turned out to be suitable candidates for this borylation platform.34 Indeed, 
borane complexes stabilized by NHCs featuring different electronic properties, steric 
hindrance and/or lipophilicity all served as good substrates for the target borylation reaction, 
furnishing the desired products with up to 1160 TTN and enantioselectivities up to 97.1:2.9 
e.r. For instance, fluorine-containing alkyl groups (e.g., 2c), which are electron-withdrawing 
and usually exhibit very different lipophilicity and hydrophilicity relative to general aliphatic 
alkyl groups, were found to be compatible with the whole-cell reaction conditions.
To explore the longevity of the biocatalyst, we tried portionwise addition of the two 
substrates. Every 1.5 hours, we added an additional aliquot corresponding to 12.5 mM of 
each substrate to the reaction. Over 20 additions, we observed continuous and steadily 
increasing product formation, which indicates that the catalyst maintained function over 30 
hours (Figure 4C). However, we did notice that enantioselectivities decreased. Covalent 
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modification of the protein backbone by carbene species and non-covalent binding of borane 
substrate or product to the protein may cause structural changes that compromise 
stereocontrol.35 Further reaction engineering and optimization, such as using a flow system 
to maintain consistent concentrations of reagents, may be able to address this selectivity 
drop.
Given that the 5-membered cyclic lactone-carbene worked so well for this biocatalytic B–H 
insertion, we wondered whether other cyclic carbenes, particularly lactone-carbenes with 
different ring sizes, would also be accepted. The 6- and 7-membered lactone diazos 4 and 6 
were readily prepared from the corresponding lactones and used as cyclic carbene precursors 
for testing B–H insertion using variant BORLAC (Figure 4A). The 6-membered lactone-
carbene showed high reactivities (up to 1190 TTN and 96.1:3.9 e.r.) for the desired 
borylation with three different borane substrates. Additionally, enzymatic borylation with 
both 5- and 6-membered lactone carbenes was readily scalable to millimole level, affording 
the desired products in high isolated yields (Figure 4B). However, with one additional 
carbon in the ring, the 7-membered lactone-carbene behaved in a completely different 
manner: BORLAC exhibited only low activity with this carbene precursor (<50 TTN).
To understand the origins of this dramatic impact of ring size on Rma cyt c-catalyzed 
lactone-carbene B–H insertion chemistry, we employed DFT calculations to compare the 
structures and the electronic properties of three lactonetype IPCs. Unlike 5-membered 
lactone-based IPC2, which takes on a rigid planar structure, 6-membered lactone-carbene 
IPC3 showed a slightly flexible structure with a dihedral angle d(Fe-C-C-O) of 60° in the 
ground OSS state, while its triplet state still possesses a near-planar geometry (Figure 5). 
However, 7-membered lactone IPC4 takes on highly twisted conformations with d(Fe-C-C-
O) from 47° to 73° in all electronic states.36 It is apparent that none of the electronic states 
in IPC4 shares a similar structure with IPC2. This may explain why BORLAC, which was 
evolved for the 5membered lactone carbene, did not exhibit high reactivity towards 
borylation with the 7-membered lactone carbene. But this does not necessarily mean that 
Rma cyt c cannot be engineered to accommodate the 7-membered lactone carbene for B–H 
insertion; further engineering using BORLAC as a starting template could well lead to 
variants with improved reactivity on this 7-membered lactone carbene.
In conclusion, we have expanded the scope of carbenes for biocatalytic B–H insertion 
chemistry to include cyclic lactone carbenes.37 With further development of Rma cyt c based 
biocatalytic platforms, we accessed a range of organoborons at preparative scales and with 
unprecedented catalytic efficiencies (up to 24,500 TTN) and high enantioselectivities (up to 
97.1:2.9 e.r.). Computational studies provided insights into the conformations and electronic 
states of cyclic carbene intermediates with different ring sizes. This mechanistic 
understanding together with the new biocatalyst variants identified should promote further 
expansion of carbene scope for borylation and other carbine-transfer reactions.
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Chen et al. Page 4






















A.Z.Z. thanks the Caltech SURF program. Calculations were performed on the high-performance computing 
system at the Department of Chemistry, Zhejiang University. We thank R. D. Lewis and R. K. Zhang for helpful 
discussions and comments. We also thank the Caltech Mass Spectrometry Laboratory.
Funding Information
Financial support from the NSF Division of Molecular and Cellular Biosciences grant MCB-1513007, National 
Natural Science Foundation of China (21702182), Zhejiang University, the Chinese “Thousand Youth Talents 
Plan”, and the “Fundamental Research Funds for the Central Universities” is gratefully acknowledged. K.C. thanks 
the Resnick Sustainability Institute at Caltech for fellowship support. X.H. is supported by an NIH pathway to 
independence award (grant K99GM129419).
References
(1). Fyfe JWB; Watson AJB Chem 2017, 3, 31.
(2). Leonori D; Aggarwal VK Acc. Chem. Res 2014, 47, 3174. [PubMed: 25262745] 
(3). Lennox AJJ; Lloyd-Jones GC Chem. Soc. Rev 2014, 43, 412. [PubMed: 24091429] 
(4). Brown HC; Ramachandran PV Pure Appl. Chem 1991, 63, 307.
(5). Brown HC; Jadhav PK; Mandal AK Tetrahedron 1981, 37, 3547.
(6). Miyaura N; Suzuki A Chem. Rev 1995, 95, 2457.
(7). Martin R; Buchwald SL Acc. Chem. Res 2008, 41, 1461. [PubMed: 18620434] 
(8). Boronic Acids: Preparation and Applications in Organic Synthesis and Medicine; Hall DG, Ed.; 
Wiley-VCH: Weinheim, 2005.
(9). Das BC; Thapa P; Karki R; Schinke C; Das S; Kambhampati S; Banerjee SK; Veldhuizen PV; 
Verma A; Weiss LM; Evans T Future Med. Chem 2013, 5, 653. [PubMed: 23617429] 
(10). Dembitsky VM; Al Quntar AA; Srebnik M Chem. Rev 2011, 111, 209. [PubMed: 21171664] 
(11). Li X; Curran DP J. Am. Chem. Soc 2013, 135, 12076. [PubMed: 23865527] 
(12). Cheng Q-Q; Zhu S-F; Zhang Y-Z; Xie X-L; Zhou Q-LJ Am. Chem. Soc 2013, 135, 14094.
(13). Chen D; Zhang X; Qi W-Y; Xu B; Xu M-H J. Am. Chem. Soc 2015, 137, 5268. [PubMed: 
25726987] 
(14). Hyde S; Veliks J; Liégault B; Grassi D; Taillefer M; Gouverneur V Angew. Chem. Int. Ed 2016, 
55, 3785.
(15). Yang J-M; Li Z-Q; Li M-L; He Q; Zhu S-F; Zhou Q-LJ Am. Chem. Soc 2017, 139, 3784.
(16). Pang Y; He Q; Li Z-Q; Yang J-M; Yu J-H; Zhu S-F; Zhou Q-LJ Am. Chem. Soc 2018, 140, 
10663.
(17). Allen TH; Kawamoto T; Gardner S; Geib SJ; Curran DP Org. Lett. 2017, 19, 3680. [PubMed: 
28641014] 
(18). Yang J-M; Zhao Y-T; Li Z-Q; Gu X-S; Zhu S-F; Zhou Q-L ACS Catal. 2018, 8, 7351.
(19). Kan SBJ; Huang X; Gumulya Y; Chen K; Arnold FH Nature 2017, 552, 132. [PubMed: 
29186119] 
(20). Huang X; Garcia-Borràs M; Miao K; Kan SBJ; Zutshi A; Houk KN; Arnold FH ChemRxiv 2018, 
DOI: 10.26434/chemrxiv.7130852.
(21). Chen K; Zhang S-Q; Brandenberg OF; Hong X; Arnold FH J. Am. Chem. Soc. 2018, 140, 16402.
(22). Coelho PS; Brustad EM; Kannan A; Arnold FH Science 2013, 339, 307. [PubMed: 23258409] 
(23). Coelho PS; Wang ZJ; Ener ME; Baril SA; Kannan A; Arnold FH; Brustad EM Nat. Chem. Biol 
2013, 9, 485. [PubMed: 23792734] 
(24). Brandenberg OF; Fasan R; Arnold FH Curr. Opin. Biotechnol 2017, 47, 102. [PubMed: 
28711855] 
(25). Chen K; Huang X; Kan SBJ; Zhang RK; Arnold FH Science 2018, 360, 71. [PubMed: 29622650] 
(26). Kan SBJ; Lewis RD; Chen K; Arnold FH Science 2016, 354, 1048. [PubMed: 27885032] 
Chen et al. Page 5





















(27). Lewis RD; Garcia-Borras M; Chalkley MJ; Buller AR; Houk KN; Kan SBJ; Arnold FH Proc. 
Natl. Acad. Sci. U.S.A 2018, 115, 7308. [PubMed: 29946033] 
(28). Khade RL; Fan W; Ling Y; Yang L; Oldfield E; Zhang Y Angew. Chem. Int. Ed 2014, 53, 7574.
(29). Sharon DA; Mallick D; Wang B; Shaik SJ Am. Chem. Soc 2016, 138, 9597.
(30). Wei Y; Tinoco A; Steck V; Fasan R; Zhang YJ Am. Chem. Soc 2018, 140, 1649.
(31). Stelter M; Melo AMP; Pereira MM; Gomes CM; Hreggvidsson GO; Hjorleifsdottir S; Saraiva 
LM; Teixeira M; Archer M Biochemistry 2008, 47, 11953. [PubMed: 18855424] 
(32). Kille S; Acevedo-Rocha CG; Parra LP; Zhang Z-G; Opperman DJ; Reetz MT; Acevedo JP ACS 
Synth. Biol 2013, 2, 83. [PubMed: 23656371] 
(33). Yang J-M; Li Z-Q; Zhu S-F Chin. J. Org. Chem 2017, 37, 2481.
(34). Tehfe M-A; Monot J; Malacria M; Fensterbank L; Fouassier JP; Curran DP; Lacôte E; Lalevée J 
ACS Macro Lett. 2012, 1, 92.
(35). Renata H; Lewis RD; Sweredoski MJ; Moradian A; Hess S; Wang ZJ; Arnold FH J. Am. Chem. 
Soc 2016, 138, 12527. [PubMed: 27573353] 
(36). DeAngelis A; Dmitrenko O; Fox JM J. Am. Chem. Soc 2012, 134, 11035. [PubMed: 22676258] 
(37). General ProcedureTo a 20 mL vial were added a suspension of E. coli expressing Rma 
cytochrome c variant BORLAC (5 mL, OD600 = 15), borane (150 μL of a 400 mM stock solution 
in MeCN, 0.06 mmol), lactone diazo compound (150 μL of a 400 mM stock solution in MeCN, 
0.06 mmol), and D-glucose (50 mM) in M9-N buffer (pH 7.4) under anaerobic conditions. The 
vial was capped and shaken (480 rpm) at room temperature for 18 h. Reactions were set up in 
quadruplicate. Upon completion, reactions in replicate were combined and transferred to 50 mL 
centrifuge tubes. The reaction vials were washed with water (2 × 2 mL) followed by a mixed 
organic solvent (hexane/ethyl acetate = 1:1, 3 × 2 mL). The washing solution was combined with 
the reaction mixture in the centrifuge tubes. An additional 15 mL of hexane/ethyl acetate solvent 
was added to every tube. The tube was then vortexed (3 × 1 min) and shaken vigorously, and 
centrifuged (5,000 × g, 5 min). The organic layer was separated and the aqueous layer was 
subjected to three more rounds of extraction. The organic layers were combined, dried over 
Na2SO4 and concentrated under reduced pressure. Purification by silica gel column 
chromatography with hexane/(ethyl acetate/acetone 3:7) as eluent afforded the desired lactone-
based organoboranes. Enantiomeric ratio (e.r.) was measured by chiral HPLC. TTN was 
calculated based on measured protein concentration and isolated product yield. Product 3a was 
obtained as a white solid (41.4 mg, 89%, 1290 TTN). 1H NMR (400 MHz, CDCl3): δ = 6.83 (s, 
2 H), 4.45 (dddd, J = 10.7, 8.1, 6.8, 1.0 Hz, 1 H), 4.27 (tq, J = 9.0, 1.1 Hz, 1 H), 3.83–3.69 (m, 6 
H), 2.53–2.25 (m, 1 H), 2.01–1.93 (m, 1 H), 1.88–1.80 (m, 1 H), 1.79–1.16 (m, 2 H); 13C NMR 
(101 MHz, CDCl3): δ = 187.91, 120.62, 67.86, 36.15, 30.86; 11B NMR (128 MHz, CDCl3): δ = 
−27.08 (t, J = 89.6 Hz); HRMS (FAB+): m/z [(M + H+) – H2] calcd for C9H14O2N2B: 
193.1148; found: 193.1144; Chiral HPLC (Chiralpak IC, 40% i-PrOH in hexane, flow rate: 1.5 
mL/min, temperature: 32 °C, λ = 235 nm): tR (major) = 12.857 min, tR (minor) = 10.991 min; 
96.2:3.8 e.r.
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A. Catalytic carbene B–H insertion. B. A hemeprotein biocatalyst for carbene B–H insertion 
based on Rma cytochrome c. C. Carbenes used for biocatalytic carbene B–H insertion
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Electronic states of acyclic IPC1 and cyclic IPC2 intermediates. The Gibbs free energies 
were obtained at the B3LYP-D3(BJ)/def2-TZ-VPP//B3LYP/def2-SVP level. OSS = open-
shell singlet, CSS = closed-shell singlet
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A. Whole protein structure and active-site structure of wildtype Rma cyt c (PDB: 3CP5, ref. 
31). B. Yields and e.r. values of selected Rma cyt c variants for B–H insertion. Reactions 
were conducted in quadruplicate: suspensions of E. coli expressing Rma cyt c variants 
(OD600 = 20), 10 mM borane 2a, 10 mM lactone diazo 1, and 5 vol% acetonitrile in M9-N 
buffer (pH 7.4) at room temperature under anaerobic conditions for 18 hours. TTN refers to 
the molar ratio of total desired product, as quantified by gas chromatography-mass 
spectrometry (GC-MS) using trimethoxybenzene as internal standard, to total heme protein. 
Enantiomeric ratio (e.r.) was determined by chiral high-performance liquid chromatography 
(HPLC)
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A. Scope of lactone-carbene B–H insertion with BORLAC. Reactions were conducted in 
quadruplicate: suspension of E. coli expressing Rma cyt c variant BORLAC (OD600 = 20), 
10 mM borane 2, 10 mM lactone diazo 1, 4 or 6, and 5 vol% acetonitrile in M9-N buffer (pH 
7.4) at room temperature under anaerobic conditions for 18 hours. TTN refers to the total 
desired product, as quantified by GC-MS using trimethoxybenzene as internal standard, 
divided by total heme protein. Enantiomeric ratio (e.r.) was determined by chiral HPLC. B. 
Preparative-scale synthesis of organoborons. Reaction conditions: suspension of E. coli 
expressing Rma cyt c variant BORLAC (OD600 = 15), 12 mM borane 2a, 12 mM lactone 
diazo 1 or 4, 50 mM D-glucose and 6 vol% acetonitrile in M9-N buffer (pH 7.4) at room 
temperature under anaerobic conditions for 18 hours. Reactions were set up in quadruplicate 
and organoboron products were isolated from the combined reaction replicates. C. 
Enzymatic synthesis of organoborons with portionwise addition of substrates. Reactions 
were conducted in duplicate using the same reaction conditions as in A. above, except for 
using 2.5 M solution stocks of borane 2b and lactone diazo 1 (one portion = 2 μL of each 
substrate stock)
Chen et al. Page 10






















Comparison of 5-, 6- and 7-membered lactone-based IPCs. The Gibbs free energies were 
obtained at the B3LYP-D3(BJ)/def2-TZ-VPP//B3LYP/def2-SVP level
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